TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31082899
Drug: Negative pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative pressure wound therapy
Study: 27320956
Drug: Cardiac Resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Resynchronization Therapy Defibrillator (CRT-D)
Study: 15791520
Drug: Indinavir (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir (500 mg/m2 every 8 hours)
Study: 15791520
Drug: Ritonavir (liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (liquid formulation)
Study: 11929641
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OCs) with 50 microg ethinyl estradiol (EE)
Study: 11929641
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OCs) with 30-40 microg ethinyl estradiol (EE)
Study: 11929641
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OCs) with 20 microg ethinyl estradiol (EE)
Study: 11929641
Drug: Progestin-only pills
Normalized name: Prostin E2 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin-only pills
Study: 11929641
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives with second-generation progestins (levonorgestrel or norgestimate) and 20-30 microg EE
Study: 11929641
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives with third-generation progestins (desogestrel or gestodene) and 20-30 microg EE
Study: 10212716
Drug: Sub-Tenon's block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon's block with 2% lignocaine 1 ml containing 150 i.u. per ml of hyaluronidase with 2% plain lignocaine 2 ml and 0.5% plain bupivacaine 2 ml
Study: 10212716
Drug: Sub-Tenon's block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon's block with 2% plain lignocaine 3 ml with 0.5% plain bupivacaine 2 ml
Study: 8540977
Drug: Standard supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard supplements (for groups 1 and 2)
Study: 8540977
Drug: Increased supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased supplements (group 3)
Study: 2215985
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg/kg and Ketamine 1 mg/kg i.v.
Study: 2215985
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg/kg and Fentanyl 1.5 micrograms/kg
Study: 7000226
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of metronidazole intra-rectally 1 h preoperatively
Study: 31192722
Drug: Music Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy (n = 16)
Study: 28693614
Drug: Increasing access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increasing access to treatment
Study: 17967712
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxidized regenerated cellulose/collagen biomaterial and autologous growth factors
Study: 23391845
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention program including education on medication adherence and hypertension, and provision of a home blood pressure monitoring device.
Study: 9166129
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg oral DMSA
Study: 1540053
Drug: Transfer factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfer factor (1 mL at 3-month intervals after operation)
Study: 29154132
Drug: Dexmedetomidine (1-μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1-μg/kg over 10 min)
Study: 29154132
Drug: Dexmedetomidine (0.5-μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5-μg/kg over 10 min)
Study: 24903511
Drug: Atorvastatin reload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin reload
Study: 22614920
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS) 110 μg once daily
Study: 22614920
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS) 110 μg twice daily
Study: 15827692
Drug: gel
Normalized name: Gel
DrugBank: Sepia esculenta bone (DB16562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel
Study: 15827692
Drug: carmellose spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: carmellose spray
Study: 15827692
Drug: mucin spray
Normalized name: mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: mucin spray
Study: 10636527
Drug: Low doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low doses of diuretics (<80 mg/day of furosemide)
Study: 10636527
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of diuretics (>=80 mg/day of furosemide)
Study: 10636527
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment with diuretics prior to hospitalization
Study: 28584913
Drug: Triazolam 0.125
Normalized name: triazolam 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam 0.125 mg
Study: 28203729
Drug: Liberal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal group (LG) - early postoperative oral fluid intake with apple juice (10 ml kg−1) offered if FLACC score ≥4 in PACU
Study: 19811503
Drug: frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: frovatriptan 2.5 mg b.i.d.
Study: 19811503
Drug: frovatriptan 2.5
Normalized name: frovatriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: frovatriptan 2.5 mg q.d.
Study: 12135535
Drug: 20 mg/d
Normalized name: Valtoco, 20 mg/dose nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/d fluoxetine
Study: 17074147
Drug: One tablet
Normalized name: Hydone Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of almitrine l/d and 20 mg oryzanol 3/d
Study: 17074147
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antidepressant treatment)
Study: 15447755
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg plus Isosorbide-5-mononitrate 20 mg
Study: 11588526
Drug: Pravastatin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin, 40 mg/day for 6 months
Study: 9842024
Drug: Pemirolast potassium
Normalized name: Pemirolast Potassium
DrugBank: Pemirolast (DB00885)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pemirolast potassium (20 mg/d from 1 week before PTCA until follow-up angiography at 4 months)
Study: 1101943
Drug: Automatic Cardiff
Normalized name: AMMONIA,AROMATIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automatic Cardiff Infusion apparatus for PGE2
Study: 1101943
Drug: Non-automatic techniques
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-automatic techniques for PGE2 and oxytocin infusion
Study: 3034795
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for relapsed patients
Study: 28158579
Drug: Bevacizumab-paclitaxel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab-paclitaxel (10 mg/kg bevacizumab on Days 1 and 15, paclitaxel 90 mg/m2 on Days 1, 8, and 15, repeated every 4 weeks)
Study: 28158579
Drug: Placebo-paclitaxel (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-paclitaxel (placebo on Days 1 and 15, paclitaxel 90 mg/m2 on Days 1, 8, and 15, repeated every 4 weeks)
Study: 25509728
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment group
Study: 21164065
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg i.v. ibuprofen (infused over five to seven minutes)
Study: 21164065
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg oral ibuprofen with concomitant i.v. placebo (0.9% sodium chloride injection)
Study: 21164065
Drug: i.v. ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. ibuprofen
Study: 18640378
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BBR (90 mg/[kg d], oral) with SIMVA (6 mg/[kg d], oral)
Study: 18640378
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of BBR with SIMVA
Study: 18640378
Drug: SIMVA (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIMVA (6 mg/[kg d], oral)
Study: 16522699
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE; 0.625 mg) with 2.5 mg medroxyprogesterone acetate (MPA)
Study: 12667032
Drug: Thiazide diuretics,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazide diuretics, angiotensin II receptor blockers, ACE inhibitors
Study: 12667032
Drug: Beta-blockers and
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers and calcium-channel blockers
Study: 1654240
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units of recombinant human alpha-interferon (alpha-2a) thrice weekly for eight weeks
Study: 6137646
Drug: Live oral
Normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live oral attenuated bovine rotavirus vaccine strain RIT 4237
Study: 24593170
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg every other week plus methotrexate
Study: 24593170
Drug: CZP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 400 mg every 4 weeks plus methotrexate
Study: 17593406
Drug: Whitestrips (WS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whitestrips (WS) - 6% hydrogen peroxide gel, applied twice a day for 30 min
Study: 17593406
Drug: Vivadent Vivastyle
Normalized name: sulfur
DrugBank: Octasulfur (DB09353)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vivadent Vivastyle (VS) - 10% carbamide peroxide gel, worn for 60 min once a day
Study: 3105906
Drug: Buserelin (d‐Ser‐[TBU]6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buserelin (d‐Ser‐[TBU]6 LHRH ethylamide) prescribed in two different dosage schedules to twenty men and in a single dosage schedule to eight women
Study: 30287704
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tell Show Do (TSD) and Audiovisual Distraction (AVD)
Study: 19043140
Drug: Rosuvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (40 mg/day)
Study: 17183151
Drug: Pravastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (80 mg/day)
Study: 17006995
Drug: Senna tablet
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna tablet (180 mg)
Study: 17006995
Drug: Sodium phosphate
Normalized name: Sodium Phosphate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium phosphate solution (95 mL)
Study: 10781196
Drug: Subcutaneous Havrix(R)
Normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Havrix(R) vaccine, 720 EL.U. at time 0 and 6 months
Study: 10781196
Drug: Subcutaneous Havrix(R)
Normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Havrix(R) vaccine
Study: 10781196
Drug: Intramuscular Havrix(R)
Normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Havrix(R) vaccine, 720 EL.U. at time 0 and 6 months
Study: 10781196
Drug: Intramuscular Havrix(R)
Normalized name: Havrix
DrugBank: Hepatitis A Vaccine (DB10989)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Havrix(R) vaccine
Study: 1591977
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg) after morphine (4 mg/70 kg)
Study: 1591977
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg) after morphine (8 mg/70 kg)
Study: 1591977
Drug: Naloxone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (10 mg/70 kg) after morphine (16 mg/70 kg)
Study: 10572333
Drug: Antidepressant medication
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medication (specific type not mentioned)
Study: 31674641
Drug: High-Dose Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: High-Dose Teriparatide (40-μg daily) + Denosumab (60 mg)
Study: 31674641
Drug: Standard-Dose Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard-Dose Teriparatide (20-μg daily) + Denosumab (60 mg)
Study: 20858609
Drug: Medical Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical Therapy Alone
Study: 16569929
Drug: NaHCO3 4.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 4.2% injected as a bolus (rapid infusion)
Study: 16569929
Drug: NaHCO3 4.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 4.2% administered over a 30-min period (slow infusion)
Study: 16569929
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (rapid and slow infusion)
Study: 1450091
Drug: Nicorandil (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (10-40 mg/day, b.i.d.)
Study: 1450091
Drug: Diltiazem (60-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (60-240 mg/day, b.i.d.)
Study: 1270971
Drug: Ethanol (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (various doses)
Study: 6420817
Drug: Ethanol (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol (one dose level)
Study: 23351590
Drug: Escitalopram (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (single dose)
Study: 24892763
Drug: Control (hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (hepatitis vaccine)
Study: 22846389
Drug: Self-administered cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered cognitive behavior therapy (CBT)
Study: 23759286
Drug: Standard cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive behavior therapy (CBT)
Study: 15772927
Drug: Normal hemoglobin
Normalized name: Abnormal hemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal hemoglobin level (135-160 g/L) achieved with epoetin alfa (n=10)
Study: 15772927
Drug: Subnormal hemoglobin
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subnormal hemoglobin level (90-120 g/L) (n=14)
Study: 8775035
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine anaesthesia
Study: 28934782
Drug: Full-dose ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose ketoprofen (0.5 mg/kg every 6 hours for 48 hours)
Study: 28934782
Drug: Low-dose ketoprofen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketoprofen (half doses and quarter doses)
Study: 26424510
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment with a cast
Study: 9863784
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg inhaled zanamivir, twice daily for 5 days
Study: 9863784
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily for 5 days
Study: 31444050
Drug: LH, sex
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH, sex hormone‐binding globulin (SHBG), and anti‐Müllerian hormone (AMH)
Study: 28713084
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy + Acupuncture + Vestibular rehabilitation
Study: 28713084
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy + Acupuncture
Study: 23604551
Drug: Oral strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral strategy with sitagliptin 100 mg/day
Study: 23604551
Drug: Injectable strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable strategy with liraglutide starting at 0.6 mg/day, up-titrated to 1.2 mg/day after 1 week
Study: 21767371
Drug: Heparin-bonded endoluminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded endoluminal bypass
Study: 19836774
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg subcutaneous every 6 months for 36 months
Study: 17097943
Drug: Calcineurin inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitors (CNIs)
Study: 15236812
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no disulfiram treatment)
Study: 28129779
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (exercise, health education, socialization and group auditory rehabilitation (GAR)) attending YMCA twice a week for 10 weeks.
Study: 23537458
Drug: liraglutide 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.2 mg
Study: 23537458
Drug: liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.8 mg
Study: 25263744
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (Genotropin(®) 0.033 mg/kg/day) for 2 years
Study: 25263744
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment in the first year, double dose in the second year)
Study: 18540252
Drug: L-T4 therapy
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-T4 therapy with appropriate doses, improvement of clinical findings, normalization of serum total T4 levels, and persistently high TSH concentrations.
Study: 18540252
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with adequate suppression of TSH (<6 mU/l) with therapy.
Study: 9845400
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg octreotide acetate
Study: 30318128
Drug: Wax bath
Normalized name: Candelilla Wax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wax bath treatment
Study: 30318128
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with daily home exercises
Study: 23149178
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg intravenous omeprazole
Study: 23149178
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg intravenous omeprazole
Study: 23149178
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of omeprazole
Study: 21718094
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump therapy started at diagnosis
Study: 21718094
Drug: Standard multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multiple daily insulin injections (MDIs)
Study: 19786862
Drug: Morphine (10‐70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10‐70 microg x kg(‐1) x h(‐1))
Study: 15818288
Drug: Gatifloxacin 10
Normalized name: GATIFLOXACIN 10MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 10 mg/kg once daily for 10 days
Study: 15818288
Drug: Amoxicillin/clavulanate 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 90 mg/6.4 mg in 2 divided doses for 10 days
Study: 12861138
Drug: 17beta-estradiol tablet
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol tablet placed in the inner one third of the vagina
Study: 12861138
Drug: 17beta-estradiol tablet
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17beta-estradiol tablet placed in the outer one third of the vagina
Study: 9824602
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg twice daily for five days
Study: 9824602
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily for five days
Study: 159510
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period with no treatment
Study: 2496740
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg recombinant tissue plasminogen activator (rt-PA) over five hours
Study: 20362978
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy techniques adherence (cognitive methods and negotiating content/structuring sessions)
Study: 12172954
Drug: Intra-articular high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular high molecular weight hyaluronan injection after arthrocentesis
Study: 12172954
Drug: No arthrocentesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: No arthrocentesis before hyaluronan injection
Study: 7873109
Drug: Dance-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance-based exercise program (12 weeks, twice weekly)
Study: 2240504
Drug: Prolonged infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged infusions of propofol
Study: 359081
Drug: Mianserin 20
Normalized name: mianserin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 20 mg three times daily plus placebo lithium tablets
Study: 359081
Drug: Lithium tablets
DrugBank: Lithium succinate (DB14508)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium tablets once daily plus placebo mianserin tablets